Similarly, resistance to tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma and EGFR mutation-positive lung adenocarcinomas was counteracted by PHGDH knockdown. Here, EGFR is linked to hepatocellular carcinoma.